Cogent Biosciences Files 8-K on Financial Condition
Ticker: COGT · Form: 8-K · Filed: Feb 26, 2024 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | 8-K |
| Filed Date | Feb 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, 8-K, corporate-update
TL;DR
**Cogent Biosciences just dropped an 8-K on their financials, standard stuff, but good to know they're keeping us updated.**
AI Summary
Cogent Biosciences, Inc. filed an 8-K on February 26, 2024, reporting on its results of operations and financial condition. The filing indicates the company's current business address is 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, with a business phone number of (617) 945-5576. This report is a standard disclosure under the Securities Exchange Act of 1934, providing an update on the company's financial status.
Why It Matters
This filing provides an update on Cogent Biosciences' financial health, which is crucial for investors to assess the company's performance and future prospects. It ensures transparency regarding the company's operational results.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial condition and results of operations, not indicating any specific new risks or events.
Key Players & Entities
- Cogent Biosciences, Inc. (company) — registrant
- February 26, 2024 (date) — date of report
- 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451 (address) — principal executive offices
- (617) 945-5576 (phone_number) — registrant's telephone number
- Delaware (location) — state of incorporation
FAQ
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 26, 2024.
What is the business address of Cogent Biosciences, Inc. as stated in the filing?
The business address is 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451.
What items of information were reported in this 8-K?
The 8-K reported on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What is the Commission File Number for Cogent Biosciences, Inc.?
The Commission File Number is 001-38443.
What is the registrant's telephone number?
The registrant's telephone number is (617) 945-5576.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-02-26 08:30:56
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 Par Value COGT The Nasdaq Global Se
Filing Documents
- cogt-20240226.htm (8-K) — 55KB
- cogt-ex99_1.htm (EX-99.1) — 131KB
- img214414700_0.jpg (GRAPHIC) — 76KB
- 0000950170-24-019754.txt ( ) — 421KB
- cogt-20240226.xsd (EX-101.SCH) — 28KB
- cogt-20240226_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 26, 2024, Cogent Biosciences, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results for the quarter and year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Cogent Biosciences, Inc. on February 26, 2024, furnished herewith. 104 The cover page from the Company's Current Report on Form 8-K formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 26, 2024 COGENT BIOSCIENCES, INC. By: /s/ John Green John Green Chief Financial Officer